The challenges of marketing traditional medicines

Traditional healer's hut Copyright: Steve Allison

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>The challenges of marketing traditional medicines</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p>In recent years a number of biotech companies from developing nations have tried to market their traditional medicines to the developed world.</p>
<p>
<p2>But in the US at least, the tremendous costs of international clinical trials and strict regulations of the Food and Drug Administration (FDA) has meant that none has so far succeeded in their venture, reports Paroma Basu in this article in <em>Nature Biotechnology</em>. </p2></p>
<p> </p>
<p>
<p2>The only way to avoid huge initial outlay — developing a drug in the US costs about $900 million — is to market the drugs as dietary supplements. No clinical trial is required, but dietary supplements can only claim to prevent a disease’s symptoms, not cure it. Also, recent concerns over the safety of these supplements have made regulators in the developed world even more suspicious. </p2></p>
<p> </p>
<p>There might be signs of easier market entry in the future says Basu. This month, the traditional Chinese medicine Kanglaite will have come farther than any traditional medicine in being approved in the US. The EU and Canada have recently eased the entry of traditional medicines in the market and the FDA might formally adopt new, looser, regulations on ‘botanical drugs’.</p>
<p>Some optimists in the developing world’s biotech sector say that western medical professions and regulators are slowly warming up to their local botanical drugs. Developed nations, on their side, are hoping to bring more scientific vigour into the selection and use of traditional medicines. </p>
<p><a href="/pdffiles/nature/nbt0304-263.pdf">Link to full article</a> <img decoding="async" border="0" alt="" data-src="/scidev_images/icon_pdf.gif" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" /><noscript><img decoding="async" border="0" alt="" data-src="/scidev_images/icon_pdf.gif" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" /><noscript><img decoding="async" border="0" alt="" src="/scidev_images/icon_pdf.gif" /></noscript></noscript></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/features/the-challenges-of-marketing-traditional-medicines/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/features/the-challenges-of-marketing-traditional-medicines/",null,true])
</script>
</div>

In recent years a number of biotech companies from developing nations have tried to market their traditional medicines to the developed world.

But in the US at least, the tremendous costs of international clinical trials and strict regulations of the Food and Drug Administration (FDA) has meant that none has so far succeeded in their venture, reports Paroma Basu in this article in Nature Biotechnology.

The only way to avoid huge initial outlay — developing a drug in the US costs about $900 million — is to market the drugs as dietary supplements. No clinical trial is required, but dietary supplements can only claim to prevent a disease’s symptoms, not cure it. Also, recent concerns over the safety of these supplements have made regulators in the developed world even more suspicious.

There might be signs of easier market entry in the future says Basu. This month, the traditional Chinese medicine Kanglaite will have come farther than any traditional medicine in being approved in the US. The EU and Canada have recently eased the entry of traditional medicines in the market and the FDA might formally adopt new, looser, regulations on ‘botanical drugs’.

Some optimists in the developing world’s biotech sector say that western medical professions and regulators are slowly warming up to their local botanical drugs. Developed nations, on their side, are hoping to bring more scientific vigour into the selection and use of traditional medicines.

Link to full article